\-\ Texto\\:\\ \ \(0\)\
\-\ results\\:\ \(5\)\
\-\ \\	prior\\ to\\ mass\\ work\\-up\\,\\ the\\ following\\ lab\\ data\\ was\\ collected\\:\ \(0\)\
\-\ wbc\\ 5\\.9\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ glu\\ \\ 91\ \(0\)\
\-\ rbc\\ 4\\.44\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ bun\\ 10\ \(0\)\
\-\ hgb\\ 13\\.7\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ creat\\ 1\\.0\ \(0\)\
\-\ hct\\ 39\\.1\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ na\\+\\ \\ 140\ \(0\)\
\-\ mcv\\ 88\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ k\\+\\ \\ \\ \\ \\ 3\\.9\ \(0\)\
\-\ plt\\ 261\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ cl\\-\\ \\ \\ 107\ \(0\)\
\-\ neut\\#\\ \\ 3\\.70\\;\\ lymph\\#\\ 1\\.10\\;\\ mono\\#\\ 0\\.50\\;\\ eos\\#\\ 0\\.70\ \(0\)\
\-\ afp\\ 1\\.0\\ \\ \\(0\\.0\\-6\\.1\\)\ \(0\)\
\-\ treatment\\:\ \(3\)\
\-\ \\ \\ therapy\\ is\\ based\\ on\\ the\\ presenting\\ stage\\ of\\ the\\ disease\\.\\ \\(stages\\ discussed\\ in\\ \\"discussion\\)\\.\ \(0\)\
\-\ stage\\ ia\\,\\ iia\\:\\ radiation\\ therapy\\ or\\ combination\\ radiation\\ and\\ chemotherapy\ \(0\)\
\-\ stage\\ iiia\\:\\ radiation\\ or\\ chemotherapy\ \(0\)\
\-\ stage\\ iv\\:\\ combination\\ chemotherapy\\.\ \(0\)\
\-\ when\\ b\\ symptoms\\ are\\ present\\,\\ chemotherapy\\ is\\ recommended\\ regardless\\ of\\ stage\\.\ \(0\)\
\-\ survival\\ rates\\ by\\ stage\\:\ \(0\)\
\-\ stage\\	5\\-year\\ relative\\ survival\\ rate\ \(0\)\
\-\ i\\	90\\%\\ to\\ 95\\%\ \(0\)\
\-\ ii\\	90\\%\\ to\\ 95\\%\ \(0\)\
\-\ iii\\	85\\%\\ to\\ 90\\%\ \(0\)\
\-\ iv\\	about\\ 80\\%\ \(0\)\
\-\ chest\\ x\\-ray\\ revealed\\ r\\ sided\\ medistinal\\ mass\\ without\\ evidence\\ of\\ any\\ other\\ acute\\ cardiopulmonary\\ process\\ \\.\ \(0\)\
\-\ \\ \\ \\ subsequently\\,\\ a\\ biopsy\\ of\\ the\\ mediastinal\\ mass\\ was\\ performed\\.\\ initial\\ frozen\\ section\\ revealed\\ fibrous\\ tussue\\ with\\ lymphoid\\ population\\.\ \(0\)\
\-\ final\\ diagnosis\\:\\ \ \(0\)\
\-\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\,\\ nodular\\ sclerosing\\ cell\\ type\ \(0\)\
\-\ \\‚\\Ä\\úsections\\ show\\ thick\\ fibrotic\\ bands\\ with\\ small\\ benign\\-appearing\\ lymphocytes\\ and\\ occasional\\ eosinophils\\.\\ additionally\\,\\ there\\ are\\ widely\\ scattered\\ large\\ atypical\\ cells\\ with\\ prominent\\ nucleoli\\.\\ these\\ cells\\ are\\ positive\\ for\\ cd15\\ and\\ cd30\\;\\ negative\\ for\\ lca\\,\\ cd20\\,\\ and\\ cd3\\.\\‚\\Ä\\ù\ \(0\)\
\-\ hodgkin\\'s\\ lymphoma\ \(0\)\
\-\ malignancy\ \(256\)\
\-\ aneurysm\ \(644\)\
\-\ infectious\\ etiology\ \(7\)\
\-\ trauma\ \(1087\)\
\-\ intro\\:\\ 21\\ yo\\ white\\ female\\ presented\\ to\\ her\\ physician\\ with\\ an\\ unknown\\ chief\\ complaint\\.\\ \\ a\\ chest\\ x\\-ray\\ was\\ done\\ revealing\\ an\\ anterior\\ r\\ sided\\ mediastinal\\ mass\\.\ \(0\)\
\-\ discussion\\:\ \(1\)\
\-\ \\	hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ is\\ a\\ malignancy\\ of\\ the\\ lymphatic\\ system\\ that\\ usually\\ presents\\ with\\ cervical\\ adenopathy\\.\\ its\\ incidence\\ is\\ estimated\\ by\\ the\\ american\\ cancer\\ society\\ as\\ 7\\,880\\ cases\\ of\\ hodgkin\\'s\\ lymphoma\\ \\(4\\,330\\ men\\ and\\ 3\\,550\\ women\\)\\ diagnosed\\ in\\ the\\ u\\.s\\.\\ in\\ 2004\\,\\ less\\ than\\ 1\\%\\ of\\ all\\ cancer\\ diagnoses\\.\\ \\ \\ approximately\\ 131\\,279\\ members\\ of\\ the\\ u\\.s\\.\\ population\\ are\\ living\\ with\\ hodgkin\\'s\\ lymphoma\\.\\ \\ 85\\-90\\%\\ of\\ hodgkin\\'s\\ occurs\\ in\\ adults\\,\\ 10\\ to\\ 15\\%\\ in\\ children\\.\\ \\ it\\ is\\ more\\ common\\,\\ though\\,\\ in\\ 2\\ age\\ groups\\:\\ early\\ adulthood\\ \\(age\\ 15\\-40\\,\\ usually\\ 25\\-30\\)\\ and\\ late\\ adulthood\\ \\(after\\ age\\ 55\\)\\.\\ hodgkin\\'s\\ is\\ rare\\ before\\ 5\\ years\\ of\\ age\\.\ \(0\)\
\-\ \\	lymphoma\\ of\\ any\\ type\\ is\\ usually\\ diagnosed\\ by\\ biopsy\\ of\\ an\\ enlarged\\ lymph\\ node\\ with\\ identification\\ of\\ specific\\ reed\\-sternberg\\ cells\\ on\\ examination\\.\ \(0\)\
\-\ types\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\:\ \(0\)\
\-\ \\‚\\Ä\\¢\\	nodular\\ sclerosis\\ \\(ns\\)\\.\\ the\\ lymph\\ nodes\\ in\\ the\\ lower\\ neck\\,\\ chest\\ and\\ collarbone\\ usually\\ contain\\ normal\\ and\\ reactive\\ lymphocytes\\ and\\ reed\\-sternberg\\ cells\\ separated\\ by\\ bands\\ of\\ scar\\-like\\ tissues\\.\\ ns\\ accounts\\ for\\ 60\\-70\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ ns\\ appears\\ to\\ account\\ for\\ the\\ increase\\ in\\ hodgkin\\'s\\ cases\\ in\\ recent\\ years\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	lymphocyte\\ predominance\\ \\(lp\\)\\.\\ the\\ lymph\\ nodes\\ are\\ composed\\ largely\\ of\\ reactive\\ lymphocytes\\ and\\ malignant\\ l\\&h\\ cells\\ which\\ have\\ a\\ \\"popcorn\\"\\ appearance\\ and\\ very\\ few\\ reed\\-sternberg\\ cells\\.\\ lp\\ accounts\\ for\\ 5\\%\\ of\\ hodgkin\\'s\\ cases\\ and\\ affects\\ more\\ men\\ than\\ women\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	mixed\\ cellularity\\ \\(mc\\)\\.\\ the\\ lymph\\ nodes\\ usually\\ contain\\ reed\\-sternberg\\ cells\\ and\\ inflammatory\\ cells\\.\\ mc\\ accounts\\ for\\ 20\\-30\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	lymphocyte\\ depleted\\ \\(ld\\)\\.\\ there\\ are\\ two\\ different\\ variations\\ of\\ this\\ classification\\:\\ one\\ with\\ sheets\\ of\\ differing\\ malignant\\ cells\\;\\ the\\ other\\ with\\ few\\ reed\\-sternberg\\ cells\\ and\\ lymphocytes\\ with\\ scar\\-like\\ tissue\\.\\ accounts\\ for\\ about\\ 5\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	nodular\\ lymphocyte\\ predominant\\ \\(nlp\\)\\ hodgkin\\'s\\ lymphoma\\ \\-\\ while\\ the\\ 4\\ types\\ above\\ are\\ \\"classical\\"\\ types\\,\\ nlp\\ is\\ in\\ a\\ category\\ of\\ its\\ own\\.\\ typical\\ reed\\-sternberg\\ cells\\ are\\ rare\\ to\\ non\\-existent\\;\\ instead\\ variants\\ called\\ l\\ \\&\\ h\\ cells\\ \\(colloquially\\ \\"popcorn\\ cells\\"\\)\\ are\\ seen\\.\\ \\ \ \(0\)\
\-\ staging\\ is\\ organized\\ into\\ 4\\ categories\\:\ \(0\)\
\-\ stage\\ i\\:\\ \\ \\ \\ \\ disease\\ localized\\ to\\ single\\ lymph\\ node\\ or\\ group\ \(0\)\
\-\ stage\\ ii\\:\\ \\ \\ disease\\ involving\\ more\\ than\\ one\\ lymph\\ node\\ or\\ group\\,\\ but\\ confined\\ to\\ one\\ side\\ \ \(0\)\
\-\ \\	\\ \\ \\ \\ \\ of\\ the\\ diaphragm\ \(1\)\
\-\ stage\\ iii\\:\\ \\ disease\\ in\\ the\\ lymph\\ nodes\\ or\\ the\\ spleen\\ and\\ occurs\\ of\\ both\\ sides\\ of\\ the\\ \ \(0\)\
\-\ \\	\\ \\ \\ \\ \\ diaphragm\ \(1\)\
\-\ stage\\ iv\\:\\ \\ disease\\ involving\\ the\\ liver\\,\\ lung\\,\\ skin\\,\\ or\\ bone\\ marrow\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.4131790979874204\ \(0\)\
\-\ cells\\:\\ 0\\.28940377447781795\ \(0\)\
\-\ stage\\:\\ 0\\.25310023343925986\ \(0\)\
\-\ lymph\\:\\ 0\\.1797413038096755\ \(0\)\
\-\ of\\:\\ 0\\.14701122728280375\ \(0\)\
\-\ lymphoma\\:\\ 0\\.13766167852095637\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.12995998872522743\ \(0\)\
\-\ accounts\\:\\ 0\\.12865240973470574\ \(0\)\
\-\ ns\\:\\ 0\\.12469637119364341\ \(0\)\
\-\ cases\\:\\ 0\\.11660232254127177\ \(0\)\
\-\ the\\:\\ 0\\.11530494170540609\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.11139333324462115\ \(0\)\
\-\ are\\:\\ 0\\.09867301362815652\ \(0\)\
\-\ nodes\\:\\ 0\\.09817913626209288\ \(0\)\
\-\ 90\\:\\ 0\\.09235057020174195\ \(0\)\
\-\ usually\\:\\ 0\\.09094680603340638\ \(0\)\
\-\ and\\:\\ 0\\.08955649547694514\ \(0\)\
\-\ nlp\\:\\ 0\\.08539140766401021\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.08206443008860836\ \(0\)\
\-\ types\\:\\ 0\\.08060830736528003\ \(0\)\
\-\ in\\:\\ 0\\.07906468759034992\ \(0\)\
\-\ node\\:\\ 0\\.07450289326031684\ \(0\)\
\-\ age\\:\\ 0\\.07255783294206766\ \(0\)\
\-\ to\\:\\ 0\\.07223251701766217\ \(0\)\
\-\ is\\:\\ 0\\.07121347545936767\ \(0\)\
\-\ lp\\:\\ 0\\.06960705801638528\ \(0\)\
\-\ nodular\\:\\ 0\\.06902733639252541\ \(0\)\
\-\ popcorn\\:\\ 0\\.06812193239364159\ \(0\)\
\-\ adulthood\\:\\ 0\\.06767162620592013\ \(0\)\
\-\ iv\\:\\ 0\\.06193425649995589\ \(0\)\
\-\ bands\\:\\ 0\\.06133308703306384\ \(0\)\
\-\ for\\:\\ 0\\.061301221986622946\ \(0\)\
\-\ mc\\:\\ 0\\.06064989194036768\ \(0\)\
\-\ disease\\:\\ 0\\.06064176560273504\ \(0\)\
\-\ or\\:\\ 0\\.060308649387021025\ \(0\)\
\-\ men\\:\\ 0\\.05883970459317452\ \(0\)\
\-\ contain\\:\\ 0\\.0577908146119585\ \(0\)\
\-\ radiation\\:\\ 0\\.057441171322367625\ \(0\)\
\-\ with\\:\\ 0\\.05657656402156707\ \(0\)\
\-\ survival\\:\\ 0\\.05639667961176395\ \(0\)\
\-\ diaphragm\\:\\ 0\\.05597157299226922\ \(0\)\
\-\ group\\:\\ 0\\.05491813419139735\ \(0\)\
\-\ 95\\:\\ 0\\.05479383543925666\ \(0\)\
\-\ population\\:\\ 0\\.05467104337577842\ \(0\)\
\-\ combination\\:\\ 0\\.05362815767481523\ \(0\)\
\-\ 85\\:\\ 0\\.05330309595036577\ \(0\)\
\-\ women\\:\\ 0\\.052003851161221894\ \(0\)\
\-\ 10\\:\\ 0\\.05068588706282379\ \(0\)\
\-\ discussion\\:\\ 0\\.05060435767309318\ \(0\)\
\-\ iii\\:\\ 0\\.04989455776460607\ \(0\)\
\-\ one\\:\\ 0\\.04962819805737586\ \(0\)\
\-\ reactive\\:\\ 0\\.04959438110020056\ \(0\)\
\-\ than\\:\\ 0\\.049136258358154494\ \(0\)\
\-\ by\\:\\ 0\\.04907897126114806\ \(0\)\
\-\ few\\:\\ 0\\.04901946251420574\ \(0\)\
\-\ more\\:\\ 0\\.047596427148982115\ \(0\)\
\-\ mediastinal\\:\\ 0\\.04666162911102906\ \(0\)\
\-\ medistinal\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ tussue\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ cd15\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ cd30\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ intro\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ collarbone\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ ld\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ colloquially\\:\\ 0\\.046206570964781334\ \(0\)\
\-\ chest\\:\\ 0\\.04575393885500336\ \(0\)\
\-\ ii\\:\\ 0\\.045561144271500896\ \(0\)\
\-\ occurs\\:\\ 0\\.045561144271500896\ \(0\)\
\-\ ia\\:\\ 0\\.04415284534709284\ \(0\)\
\-\ lca\\:\\ 0\\.04415284534709284\ \(0\)\
\-\ mass\\:\\ 0\\.04414577604194044\ \(0\)\
\-\ rare\\:\\ 0\\.043623553649902724\ \(0\)\
\-\ about\\:\\ 0\\.043261002070695526\ \(0\)\
\-\ malignancy\\:\\ 0\\.043261002070695526\ \(0\)\
\-\ its\\:\\ 0\\.042759212350834346\ \(0\)\
\-\ 261\\:\\ 0\\.042695703832005105\ \(0\)\
\-\ diagnosed\\:\\ 0\\.04185895592507481\ \(0\)\
\-\ depleted\\:\\ 0\\.041565457064547805\ \(0\)\
\-\ differing\\:\\ 0\\.041565457064547805\ \(0\)\
\-\ malignant\\:\\ 0\\.041192253462860456\ \(0\)\
\-\ biopsy\\:\\ 0\\.04050625338019667\ \(0\)\
\-\ involving\\:\\ 0\\.04047614868878894\ \(0\)\
\-\ iiia\\:\\ 0\\.039861187971667954\ \(0\)\
\-\ sheets\\:\\ 0\\.039861187971667954\ \(0\)\
\-\ collected\\:\\ 0\\.039184836699228884\ \(0\)\
\-\ variations\\:\\ 0\\.039184836699228884\ \(0\)\
\-\ 15\\:\\ 0\\.03904857351036521\ \(0\)\
\-\ type\\:\\ 0\\.038765372263676635\ \(0\)\
\-\ neut\\:\\ 0\\.03858825259662812\ \(0\)\
\-\ iia\\:\\ 0\\.03858825259662812\ \(0\)\
\-\ nucleoli\\:\\ 0\\.03858825259662812\ \(0\)\
\-\ cd20\\:\\ 0\\.03858825259662812\ \(0\)\
\-\ cancer\\:\\ 0\\.03848987337323714\ \(0\)\
\-\ eos\\:\\ 0\\.038054589931771576\ \(0\)\
\-\ organized\\:\\ 0\\.038054589931771576\ \(0\)\
\-\ revealed\\:\\ 0\\.037890277013276304\ \(0\)\
\-\ glu\\:\\ 0\\.037571833329597015\ \(0\)\
\-\ cellularity\\:\\ 0\\.037571833329597015\ \(0\)\
\-\ any\\:\\ 0\\.037346241800746915\ \(0\)\
\-\ sided\\:\\ 0\\.03717120122629105\ \(0\)\
\-\ mono\\:\\ 0\\.03713111108154039\ \(0\)\
\-\ frozen\\:\\ 0\\.03713111108154039\ \(0\)\
\-\ creat\\:\\ 0\\.03672568591431628\ \(0\)\
\-\ variants\\:\\ 0\\.03635032083889173\ \(0\)\
\-\ fibrotic\\:\\ 0\\.03567396956645266\ \(0\)\
\-\ eosinophils\\:\\ 0\\.03567396956645266\ \(0\)\
\-\ society\\:\\ 0\\.03567396956645266\ \(0\)\
\-\ years\\:\\ 0\\.03542233142593184\ \(0\)\
\-\ lymphoid\\:\\ 0\\.03536689915176762\ \(0\)\
\-\ members\\:\\ 0\\.03536689915176762\ \(0\)\
\-\ regardless\\:\\ 0\\.03507738546385189\ \(0\)\
\-\ classical\\:\\ 0\\.03507738546385189\ \(0\)\
\-\ categories\\:\\ 0\\.034296595221203235\ \(0\)\
\-\ 107\\:\\ 0\\.034060966196820794\ \(0\)\
\-\ separated\\:\\ 0\\.034060966196820794\ \(0\)\
\-\ mcv\\:\\ 0\\.03383581310296006\ \(0\)\
\-\ cardiopulmonary\\:\\ 0\\.03383581310296006\ \(0\)\
\-\ sections\\:\\ 0\\.033620243948764165\ \(0\)\
\-\ living\\:\\ 0\\.033620243948764165\ \(0\)\
\-\ widely\\:\\ 0\\.03341347603153805\ \(0\)\
\-\ category\\:\\ 0\\.033214818781540055\ \(0\)\
\-\ therapy\\:\\ 0\\.03320207352189967\ \(0\)\
\-\ an\\:\\ 0\\.03314602688581296\ \(0\)\
\-\ lymphatic\\:\\ 0\\.0330236598461634\ \(0\)\
\-\ largely\\:\\ 0\\.0330236598461634\ \(0\)\
\-\ revealing\\:\\ 0\\.032839453706115504\ \(0\)\
\-\ groups\\:\\ 0\\.03266171229011263\ \(0\)\
\-\ own\\:\\ 0\\.03266171229011263\ \(0\)\
\-\ predominant\\:\\ 0\\.03248999718130686\ \(0\)\
\-\ instead\\:\\ 0\\.032163102433676434\ \(0\)\
\-\ identification\\:\\ 0\\.0320072405791323\ \(0\)\
\-\ predominance\\:\\ 0\\.0320072405791323\ \(0\)\
\-\ 91\\:\\ 0\\.0318560320189914\ \(0\)\
\-\ sides\\:\\ 0\\.0318560320189914\ \(0\)\
\-\ 140\\:\\ 0\\.0317092069386582\ \(0\)\
\-\ composed\\:\\ 0\\.03142773949644039\ \(0\)\
\-\ plt\\:\\ 0\\.03103285566621913\ \(0\)\
\-\ stages\\:\\ 0\\.030907784852404554\ \(0\)\
\-\ confined\\:\\ 0\\.030907784852404554\ \(0\)\
\-\ chief\\:\\ 0\\.03055009906404457\ \(0\)\
\-\ diagnoses\\:\\ 0\\.03055009906404457\ \(0\)\
\-\ afp\\:\\ 0\\.03043627156361836\ \(0\)\
\-\ sclerosing\\:\\ 0\\.03043627156361836\ \(0\)\
\-\ was\\:\\ 0\\.03020873413546868\ \(0\)\
\-\ rates\\:\\ 0\\.030109376815987937\ \(0\)\
\-\ other\\:\\ 0\\.030009440408404187\ \(0\)\
\-\ estimated\\:\\ 0\\.030004937845778356\ \(0\)\
\-\ classification\\:\\ 0\\.02970395164876383\ \(0\)\
\-\ affects\\:\\ 0\\.02960747043447497\ \(0\)\
\-\ 88\\:\\ 0\\.029512792713387172\ \(0\)\
\-\ staging\\:\\ 0\\.029512792713387172\ \(0\)\
\-\ account\\:\\ 0\\.02941985229658726\ \(0\)\
\-\ rbc\\:\\ 0\\.029064259961698563\ \(0\)\
\-\ discussed\\:\\ 0\\.02865223530090021\ \(0\)\
\-\ data\\:\\ 0\\.02834516488621517\ \(0\)\
\-\ final\\:\\ 0\\.02834516488621517\ \(0\)\
\-\ spleen\\:\\ 0\\.02812649306080331\ \(0\)\
\-\ hgb\\:\\ 0\\.028055651198299444\ \(0\)\
\-\ bun\\:\\ 0\\.027848883281073326\ \(0\)\
\-\ occasional\\:\\ 0\\.027848883281073326\ \(0\)\
\-\ thick\\:\\ 0\\.027459067095698675\ \(0\)\
\-\ hct\\:\\ 0\\.02739691771962833\ \(0\)\
\-\ late\\:\\ 0\\.027274860955650786\ \(0\)\
\-\ 2004\\:\\ 0\\.027214918118757862\ \(0\)\
\-\ adults\\:\\ 0\\.026981998434157415\ \(0\)\
\-\ called\\:\\ 0\\.026981998434157415\ \(0\)\
\-\ different\\:\\ 0\\.026442647828667575\ \(0\)\
\-\ section\\:\\ 0\\.02634134223969103\ \(0\)\
\-\ lab\\:\\ 0\\.026096603301698745\ \(0\)\
\-\ localized\\:\\ 0\\.025955242203127\ \(0\)\
\-\ relative\\:\\ 0\\.02559650041338684\ \(0\)\
\-\ physician\\:\\ 0\\.025343192101939832\ \(0\)\
\-\ scattered\\:\\ 0\\.025141368168123988\ \(0\)\
\-\ though\\:\\ 0\\.0251019507660672\ \(0\)\
\-\ complaint\\:\\ 0\\.02502402445054742\ \(0\)\
\-\ incidence\\:\\ 0\\.024871678813153643\ \(0\)\
\-\ 55\\:\\ 0\\.024834297753438945\ \(0\)\
\-\ subsequently\\:\\ 0\\.02465142191165259\ \(0\)\
\-\ american\\:\\ 0\\.02465142191165259\ \(0\)\
\-\ adenopathy\\:\\ 0\\.024304360804529485\ \(0\)\
\-\ marrow\\:\\ 0\\.02401112140066668\ \(0\)\
\-\ mixed\\:\\ 0\\.02391702995316038\ \(0\)\
\-\ additionally\\:\\ 0\\.023794233378971682\ \(0\)\
\-\ atypical\\:\\ 0\\.023704050985981637\ \(0\)\
\-\ children\\:\\ 0\\.023674343507263197\ \(0\)\
\-\ before\\:\\ 0\\.023358568655650454\ \(0\)\
\-\ etiology\\:\\ 0\\.023275758463430638\ \(0\)\
\-\ infectious\\:\\ 0\\.023248453218858094\ \(0\)\
\-\ increase\\:\\ 0\\.023194280396564862\ \(0\)\
\-\ 21\\:\\ 0\\.023087642550435487\ \(0\)\
\-\ there\\:\\ 0\\.022993056140970986\ \(0\)\
\-\ recommended\\:\\ 0\\.022983203580225903\ \(0\)\
\-\ done\\:\\ 0\\.022983203580225903\ \(0\)\
\-\ tissues\\:\\ 0\\.022780572135750448\ \(0\)\
\-\ prominent\\:\\ 0\\.022755803819394797\ \(0\)\
\-\ presenting\\:\\ 0\\.02263374705541726\ \(0\)\
\-\ 80\\:\\ 0\\.022538176095529567\ \(0\)\
\-\ results\\:\\ 0\\.022514562483522165\ \(0\)\
\-\ fibrous\\:\\ 0\\.022444375070350776\ \(0\)\
\-\ typical\\:\\ 0\\.02232951503285002\ \(0\)\
\-\ single\\:\\ 0\\.02221720199217547\ \(0\)\
\-\ system\\:\\ 0\\.022042525696146113\ \(0\)\
\-\ aneurysm\\:\\ 0\\.021999781893101793\ \(0\)\
\-\ rate\\:\\ 0\\.02189447434523396\ \(0\)\
\-\ unknown\\:\\ 0\\.02189447434523396\ \(0\)\
\-\ specific\\:\\ 0\\.02189447434523396\ \(0\)\
\-\ process\\:\\ 0\\.02167022759665643\ \(0\)\
\-\ skin\\:\\ 0\\.021493861635000548\ \(0\)\
\-\ appears\\:\\ 0\\.02115854808590406\ \(0\)\
\-\ based\\:\\ 0\\.020929477962537406\ \(0\)\
\-\ above\\:\\ 0\\.020844060919718785\ \(0\)\
\-\ early\\:\\ 0\\.020827149015520876\ \(0\)\
\-\ very\\:\\ 0\\.02072684651806195\ \(0\)\
\-\ cervical\\:\\ 0\\.020693848938154964\ \(0\)\
\-\ sclerosis\\:\\ 0\\.020580021437728756\ \(0\)\
\-\ wbc\\:\\ 0\\.02042172384829677\ \(0\)\
\-\ side\\:\\ 0\\.01996026416860497\ \(0\)\
\-\ liver\\:\\ 0\\.0199318881246321\ \(0\)\
\-\ enlarged\\:\\ 0\\.019696902248063572\ \(0\)\
\-\ less\\:\\ 0\\.01965654258749757\ \(0\)\
\-\ recent\\:\\ 0\\.01956360217069766\ \(0\)\
\-\ inflammatory\\:\\ 0\\.01953735801560248\ \(0\)\
\-\ initial\\:\\ 0\\.019382686131838318\ \(0\)\
\-\ white\\:\\ 0\\.01906293708574811\ \(0\)\
\-\ positive\\:\\ 0\\.019039157180089646\ \(0\)\
\-\ while\\:\\ 0\\.018673120900373458\ \(0\)\
\-\ examination\\:\\ 0\\.01848891476032557\ \(0\)\
\-\ approximately\\:\\ 0\\.018435987313199117\ \(0\)\
\-\ show\\:\\ 0\\.018342089679992374\ \(0\)\
\-\ yo\\:\\ 0\\.018050853458272707\ \(0\)\
\-\ her\\:\\ 0\\.018050853458272707\ \(0\)\
\-\ negative\\:\\ 0\\.017887603535961555\ \(0\)\
\-\ neck\\:\\ 0\\.017674791333290644\ \(0\)\
\-\ lung\\:\\ 0\\.01757608809194194\ \(0\)\
\-\ when\\:\\ 0\\.01745318509780594\ \(0\)\
\-\ on\\:\\ 0\\.017452505120371692\ \(0\)\
\-\ appearance\\:\\ 0\\.017418610829761184\ \(0\)\
\-\ following\\:\\ 0\\.017333193786942563\ \(0\)\
\-\ all\\:\\ 0\\.017199453724291307\ \(0\)\
\-\ two\\:\\ 0\\.0171583739321914\ \(0\)\
\-\ performed\\:\\ 0\\.01709333148976738\ \(0\)\
\-\ presented\\:\\ 0\\.016848897403451486\ \(0\)\
\-\ trauma\\:\\ 0\\.016780087295515136\ \(0\)\
\-\ cell\\:\\ 0\\.016528260931370997\ \(0\)\
\-\ evidence\\:\\ 0\\.016399842798207737\ \(0\)\
\-\ common\\:\\ 0\\.016385773037489497\ \(0\)\
\-\ these\\:\\ 0\\.01631600457074198\ \(0\)\
\-\ prior\\:\\ 0\\.016165815086032896\ \(0\)\
\-\ anterior\\:\\ 0\\.016132293384581393\ \(0\)\
\-\ both\\:\\ 0\\.016112286338417017\ \(0\)\
\-\ symptoms\\:\\ 0\\.015808740841362356\ \(0\)\
\-\ bone\\:\\ 0\\.015765048920150623\ \(0\)\
\-\ acute\\:\\ 0\\.01563013485070488\ \(0\)\
\-\ into\\:\\ 0\\.015359145709360339\ \(0\)\
\-\ without\\:\\ 0\\.015240094540433548\ \(0\)\
\-\ tissue\\:\\ 0\\.015156739220942907\ \(0\)\
\-\ diagnosis\\:\\ 0\\.014978047627549342\ \(0\)\
\-\ small\\:\\ 0\\.014904103093829515\ \(0\)\
\-\ present\\:\\ 0\\.014826056702197563\ \(0\)\
\-\ it\\:\\ 0\\.014790042559398914\ \(0\)\
\-\ lower\\:\\ 0\\.01476447405178953\ \(0\)\
\-\ large\\:\\ 0\\.014476944403193638\ \(0\)\
\-\ have\\:\\ 0\\.014433755135912765\ \(0\)\
\-\ but\\:\\ 0\\.014287749277179063\ \(0\)\
\-\ after\\:\\ 0\\.014016581374029117\ \(0\)\
\-\ female\\:\\ 0\\.013942317965029715\ \(0\)\
\-\ presents\\:\\ 0\\.013899136879957896\ \(0\)\
\-\ treatment\\:\\ 0\\.013763380395850495\ \(0\)\
\-\ seen\\:\\ 0\\.01360270054292401\ \(0\)\
\-\ which\\:\\ 0\\.013138040895323229\ \(0\)\
\-\ that\\:\\ 0\\.012538579939692734\ \(0\)\
\-\ normal\\:\\ 0\\.011796913634521348\ \(0\)\
\-\ as\\:\\ 0\\.0116074374601574\ \(0\)\
\-\ this\\:\\ 0\\.009928235467504995\ \(0\)\
